• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丁丙诺啡动力学

Buprenorphine kinetics.

作者信息

Bullingham R E, McQuay H J, Moore A, Bennett M R

出版信息

Clin Pharmacol Ther. 1980 Nov;28(5):667-72. doi: 10.1038/clpt.1980.219.

DOI:10.1038/clpt.1980.219
PMID:7438685
Abstract

Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg intramuscularly; again, plasma levels were measured for 3 hr. The data fitted closely to a triexponential decay curve. There was a very fast initial phase, with a half-life (t1/2) of 2 min. The terminal t1/2 was slow, approximately 3 hr. Comparison of the kinetics of the same patient, awake and anesthetized, showed that the clearance was significantly lower in the anesthetized state. A notable feature of the drug given intramuscularly is rapid systemic availability, so that peaks are obtained in 2 to 5 min, and in 10 min the resulting levels are the same as for the intravenous and intramuscular routes.

摘要

采用放射免疫分析法测定了外科手术患者中丁丙诺啡的动力学。对24例术中接受0.3mg丁丙诺啡的患者血浆中的丁丙诺啡进行了测定。3小时后,其中10例患者为缓解术后疼痛又静脉注射了0.3mg丁丙诺啡,11例患者接受了0.3mg肌肉注射;同样,测量血浆水平3小时。数据与三指数衰减曲线拟合得非常紧密。有一个非常快速的初始阶段,半衰期(t1/2)为2分钟。终末t1/2较慢,约为3小时。对同一患者清醒和麻醉状态下的动力学进行比较,结果显示麻醉状态下的清除率显著降低。肌肉注射该药的一个显著特点是全身快速起效,因此在2至5分钟内达到峰值,10分钟时达到的水平与静脉注射和肌肉注射途径相同。

相似文献

1
Buprenorphine kinetics.丁丙诺啡动力学
Clin Pharmacol Ther. 1980 Nov;28(5):667-72. doi: 10.1038/clpt.1980.219.
2
The systemic bioavailability of buprenorphine by various routes of administration.丁丙诺啡经不同给药途径的全身生物利用度。
J Pharm Pharmacol. 1981 Aug;33(8):500-6. doi: 10.1111/j.2042-7158.1981.tb13848.x.
3
Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis.术后使用舌下含服丁丙诺啡:临床观察与初步药代动力学分析
Br J Clin Pharmacol. 1981 Aug;12(2):117-22. doi: 10.1111/j.1365-2125.1981.tb01189.x.
4
Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant.
Xenobiotica. 1985 Apr;15(4):287-97. doi: 10.3109/00498258509045363.
5
Clinical actions of fentanyl and buprenorphine. The significance of receptor binding.芬太尼和丁丙诺啡的临床作用。受体结合的意义。
Br J Anaesth. 1985 Feb;57(2):192-6. doi: 10.1093/bja/57.2.192.
6
Buprenorphine in end stage renal failure.布托啡诺用于终末期肾衰竭
Anaesthesia. 1985 Sep;40(9):914. doi: 10.1111/j.1365-2044.1985.tb11063.x.
7
Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons.
Eur J Drug Metab Pharmacokinet. 1980;5(4):233-9. doi: 10.1007/BF03189469.
8
(-)-2-Hydroxy-n-cyclopropylmethylmorphinan: radioimmunoassay and phamacokinetic profile.(-)-2-羟基-N-环丙基甲基吗啡喃:放射免疫分析及药代动力学特征
Clin Pharmacol Ther. 1978 Nov;24(5):622-7. doi: 10.1002/cpt1978245622.
9
Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.术后使用舌下含服丁丙诺啡:十小时血浆药物浓度分析
Br J Clin Pharmacol. 1982 May;13(5):665-73. doi: 10.1111/j.1365-2125.1982.tb01434.x.
10
Buprenorphine : characteristics of binding sites in the rat central nervous system.丁丙诺啡:大鼠中枢神经系统中结合位点的特征
Life Sci. 1981 Dec 28;29(26):2699-708. doi: 10.1016/0024-3205(81)90529-4.

引用本文的文献

1
Mechanisms of altered hepatic drug disposition during pregnancy: small molecules.孕期肝脏药物处置改变的机制:小分子
Expert Opin Drug Metab Toxicol. 2025 Apr;21(4):445-462. doi: 10.1080/17425255.2025.2470792. Epub 2025 Feb 26.
2
Influence of Age, Gender and Body Mass Index on Intravenous Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery.年龄、性别和体重指数对接受骨科手术儿童中丁丙诺啡静脉药代动力学的影响。
Dose Response. 2024 Aug 8;22(3):15593258241266469. doi: 10.1177/15593258241266469. eCollection 2024 Jul-Sep.
3
Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.
经口丁丙诺啡生理药代动力学模型的建立与验证:考虑到非线 性生物利用度,该模型适用于健康成年志愿者
Drug Metab Dispos. 2024 Jul 16;52(8):785-796. doi: 10.1124/dmd.124.001643.
4
Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder.盐酸纳美芬:对治疗酒精和阿片类物质使用障碍的潜在意义。
Subst Abuse Rehabil. 2024 Apr 3;15:43-57. doi: 10.2147/SAR.S431270. eCollection 2024.
5
Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling.通过基于生理药代动力学模型的母胎模型预测胎儿丁丙诺啡暴露情况。
Pharmaceutics. 2024 Mar 8;16(3):375. doi: 10.3390/pharmaceutics16030375.
6
Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed.用于急性疼痛的长效阿片类镇痛药:药代动力学证据综述。
Vet Sci. 2023 May 24;10(6):372. doi: 10.3390/vetsci10060372.
7
Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.基于生理学的药代动力学模型研究新生儿阿片类戒断综合征中成熟对丁丙诺啡药代动力学的影响。
Clin Pharmacol Ther. 2022 Feb;111(2):496-508. doi: 10.1002/cpt.2458. Epub 2021 Nov 21.
8
Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.经皮下途径给予丁丙诺啡缓释每月注射剂的药物-药物相互作用风险评估。
Clin Pharmacol Drug Dev. 2021 Sep;10(9):1064-1074. doi: 10.1002/cpdd.934. Epub 2021 Mar 22.
9
Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates.丁丙诺啡在成人、儿童和早产新生儿中的基于生理的药代动力学(PBPK)建模
Pharmaceutics. 2020 Jun 23;12(6):578. doi: 10.3390/pharmaceutics12060578.
10
Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy.美沙酮维持治疗患者中丁丙诺啡-大麻相互作用。
Eur Arch Psychiatry Clin Neurosci. 2021 Aug;271(5):847-856. doi: 10.1007/s00406-019-01091-0. Epub 2020 Jan 6.